KDM4B and neoplasm: ML324 is a different KDM4 inhibitor in the arsenal; it specifically targeted KDM4B and KDM4E, suppressed prostate cancer proliferation both in vitro and in vivo, and decreased tumor volume and growth in a triple-negative breast cancer mice model [131,132,133,134,135].